A shifting paradigm in the aetiology of oral and pharyngeal cancer in Sri Lanka: a case-control study providing serologic evidence for the role of oncogenic HPV types 16 and 18

Infectious Agents and Cancer

Preethi Vidya Udagama¹  Chandrika Fernando³  Kanthi Angela Perera²  Suvanthee Kushani Gunasekera¹ 

[1] Department of Zoology, Faculty of Science, University of Colombo, Colombo 03, Sri Lanka;National Cancer Institute, Maharagama, Sri Lanka;Sri Lanka Institute for Information Technology, Colombo, Sri Lanka

关键词: Smoking;    Risk factors;    Enzyme-linked Immunosorbent assay;    HPV18;    HPV16;    Human papillomavirus (HPV);    Oral and pharyngeal cancer;    Sri Lanka;   

Others  :  1175259
DOI  :  10.1186/s13027-015-0007-z

 received in 2014-09-11, accepted in 2015-03-31,  发布年份 2015

【 摘 要 】

Background

Oral and pharyngeal cancer (OPC) of multifactorial aetiology is a major health problem globally. Ranking first in all cancers, OPC poses a significant impact on the Sri Lankan male population. As Human Papillomavirus (HPV) high risk (HR) types are found to be significant risk factors for OPC globally, the current study was undertaken to examine the association between HR-HPV16 and 18 types with OPC in Sri Lanka.

Materials and methods

Serum samples of 78 OPC patients and 51 non-cancer controls were assayed for the presence of anti-HPV16 and anti-HPV18 IgG antibodies using in-house established Enzyme Linked Immunosorbent Assays (ELISAs). The association between OPC and its risk factors i.e. HPV, smoking, alcohol, betel quid, poor dentition, was established using Chi-square test. Logistic regression was used to calculate odds ratios (OR), adjusted for the influence of other risk factors.

Results

This prototype study in Sri Lanka showed a significant risk of 15 fold in developing OPC due to HPV16/18 seropositivity after removing variability due to other factors. Oncogenic HPV18 showed a higher rate of seropositivity being detected in 32% of OPC patients, and also in 2% of non-cancer control subjects. HR-HPV16 was detected in 23% of OPC patients and in 5.88% of controls. Moreover, seven OPC patients were detected with both anti-HPV16 and anti-HPV18 antibodies. According to the logistic regression models HPV18 seropositivity was associated with a 28 fold risk in developing OPC while that of HPV16 was associated with a 6 fold increase in risk for the development of OPC. A 5 fold risk of developing OPC was also pronounced among smokers while alcohol, betel and poor dentition was not significantly associated with OPC. Statistically significant differences with regard to age, gender, smoking, alcohol, betel use, poor dentition and site specificity of the tumour was not observed between HPV seropositive and seronegative OPC patients.

Conclusions

Both in-house developed ELISAs detected significant proportions of HPV seropositives within the OPC study population suggestive of HPV as a strong risk factor for oral and pharyngeal carcinogenesis in Sri Lanka.

【 授权许可】

   
2015 Gunasekera et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]World Cancer Report. IARCPress, Lyon; 2003.
• [2]Pannone G, Santoro A, Papagerakis S, Muzio LL, De Rosa G, Bufo P: The role of human papilloma virus in the pathogenesis of head and neck squamous cell carcinoma: an overview. Infect Agents Cancer 2011, 6:4. BioMed Central Full Text
• [3]Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 19/05/2014.
• [4]Cancer Incidence data: Sri Lanka 2007. National Cancer Control Programme, Ministry of Health, Sri Lanka; 2013.
• [5]Hirota SK, Braga FPF, Penha SS, Sugaya NN, Migliari DA: Risk factors for oral squamous cell carcinoma in young and older Brazilian patients: A comparative analysis. Med Oral Patologia Oral y Cirugia Bucal 2008, 13(4):E227-E231.
• [6]Petersen PE: Oral cancer prevention and control – The approach of the World Health Organization. Oral Oncol 2009, 45(4-5):454-60.
• [7]Warnakulasuriya S: Causes of oral cancer– an appraisal of controversies. Br Dent J 2009, 207:471-475.
• [8]Bergot AS, Kassianos A, Frazer IH, Mittal D: New Approaches to Immunotherapy for HPV Associated Cancers. Cancers 2011, 3:3461-3495.
• [9]Hausen H: Papillomaviruses Causing Cancer: Evasion from Host-Cell Control in Early Events in Carcinogenesis. J Natl Cancer Inst 2000, 92:690-698.
• [10]Bosch FX, Lorincz A, Mun˜oz N, Meijer CJ, Shah KV: The causal relation between HPV and cervical cancer. J Clin Pathol 2002, 55:244-65.
• [11]Sitas F, Urban M, Stein L, Beral V, Ruff P, Hale M, Patel M, O’Connell D, Qin Yu X, Verzijden A, Marais D, Williamson A: The relationship between anti-HPV-16 IgGseropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population. Infect Agents Cancer 2007, 2:6. BioMed Central Full Text
• [12]Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J, Ferna’ndez L, Idris A, Sa’nchez MJ, Nieto A, Talamini R, Tavani A, Bosch FX, Reidel U, Snijders PJF, Meijer CJLM, Viscidi R, Mun˜oz N, Franceschi S: Human Papillomavirus and Oral Cancer: The International Agency for Research on Cancer Multicenter Study. J Natl Cancer Inst 2003, 95:1772-1793.
• [13]D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML: Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer. N Engl J Med 2007, 356:1944-56.
• [14]Gillison ML: Human papillomavirus-related Diseases: Oropharynx Cancers and Potential Implications for Adolescent HPV Vaccination. J Adolesc Health 2008, 43(4):S52-S60.
• [15]Pintos J, Black MJ, Sadeghi N, Ghadirian P, Zeitouni AG, Viscidi RP, Herrero R, Franc¸oisCoutle’e F, Franco EL: Human papilloma virus infection and oral cancer: A case-control study in Montreal, Canada. Oral Oncol 2008, 44:242-250.
• [16]Jayasooriya PR, Kurose K, Terai M, Sivagnanam K, Siriwardana S, Tilakaratne WM, Tagami J, Takagi M: Human Papillomavirus in Oral Cancer from Sri Lanka: Prevalence and relationship with clinico-pathological parameters. Oral Med Pathol 2003, 8:45-50.
• [17]Siriwardena BSMS, Tilakaratne A, Amaratunga EAPD, Tilakaratne WM: Demographic, aetiological and survival differences of oral squamous cell carcinoma in the young and the old in Sri Lanka. Oral Oncol 2006, 42(8):831-836.
• [18]Ariyawardana A, Sitheeque MAM, Ranasinghe AW, Perera I, Tilakaratne WM, Amaratunga EAPD, Yang Y, Warnakulasuriya S: Prevalence of oral cancer and pre-cancer and associated risk factors among tea estate workers in the central Sri Lanka. J Oral Pathol Med 2007, 36:581-7.
• [19]Amarasinghe HK, Usgodaarachchi US, Johnson NW, Lalloo R, Warnakulasuriya S: Betel-quid chewing with or without tobacco is a major risk factor for oral potentially malignant disorders in Sri Lanka: a case-control study. Oral Oncol 2010, 46:297-301.
• [20]Somatunga LC, Sinha DN, Sumanasekera P, Galapatti K, Rinchen S, Kahandaliyanage A, Mehta FR, Jayasuriya-Dissanayake NL: Smokeless tobacco use in Sri Lanka. Indian J Cancer 2012, 49:357-63.
• [21]Karunaratne K, Ihalagama H, Rohitha S, Molijn A, Gopala K, Schmidt JE, Chen J, Datta S, Mehta S: Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka. BMC Cancer 2014, 14:116. BioMed Central Full Text
• [22]Richardson H, Kelsall G, Tellier P, Voyer H, Abrahamowicz M, Ferenczy A, CoutléeF. and Franco EL. The natural history of type-specific human papillomavirusinfections in female university students.Cancer Epidemiology, Biomarkers &Prevention, Vol. 12, No. 6, (Jun 2003), pp. 485-490, ISSN 1055-9965.
• [23]Miranda PM, Silva NNT, Pitol BCV, Silva IDCG, Lima-Filho JL, Carvalho RF, Stocco RC, Becak W and Lima AA. Persistence or Clearance of Human Papillomavirus Infections in Women in OuroPreto, Brazil.BioMed Research International, vol. 2013:578276, 2013. doi:10.1155/2013/578276.
• [24]D’Souza G, Dempsey A: The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011, 53:S5-S11.
• [25]Koslabova E, Hamsikova E, Salakova M, Klozar J, Foltynova E, Salkova E, Rotnaglova E, Ludvikova V, Tachezy R: Markers of HPV infection and survival in patients with head and neck tumors. Int J Cancer 2013, 133:1832-1839.
• [26]Smith EM, Ritchie JM, Pawlita M, Rubenstein LM, Haugen TH, Turek LP, Hamsikova E: Human papilloma virus seropositivity and its risks of head and neck cancer. Int J Cancer 2007, 120:825-832.
• [27]Mork J, Lie C, Glattre E, Hallmans G, Jellum E, Koskella P, Moller B, Pukkala E, Schiller JT, Youngman L, Lehtinen M, Dillner J: Human papilloma virus infection as a risk factor for squamous cell carcinoma of the head and neck. N Engl J Med 2001, 344:1125-31.
• [28]Kreimer AR, Cliford GM, Boyle P, Franceschi S: Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review. Cancer Epidemiol Biomarkers Prev 2005, 14(2):467-475.
• [29]Soares RC, Oliveira MC, Souza LB, Costa AL, Medeiros SRB, Pinto LP: Human papillomavirus in oral squamous cells carcinoma in a population of 75 Brazilian patients. Am J Otolaryngol 2007, 28(6):397-40.
• [30]Chang JY, Lin M, Chiang C: High-Risk Human Papillomaviruses May Have an Important Role in Non–Oral Habits–Associated Oral Squamous Cell Carcinomas in Taiwan. Am J Clin Pathol 2003, 120:909-916.
• [31]Lee LA, Huang CG, Liao CT, Lee LY, Hsueh C, Chen TC, Lin CY, Fan KH, Wang HM, Huang SF, Chen IH, Kang CJ, Ng SH, Yang SL, Tsao KC, Chang YL, Yen TC: Human Papillomavirus-16 Infection in Advanced Oral Cavity Cancer Patients Is Related to an Increased Risk of Distant Metastases and Poor Survival. PLoS ONE 2012, 7(7):e40767.
• [32]Feller L, Wood NH, Khammissa RAG, Lemmer J: Human papillomavirus-mediated carcinogenesis and HPV-associated oral and oropharyngeal squamous cell carcinoma. Part 2: Human papillomavirus associated oral and oropharyngeal squamous cell carcinoma. Head and Face Medicine 2010, 6:15. BioMed Central Full Text
• [33]Friis RH, Sellers TA: Epidemiology for public Health Practice. Jones and Bartlett Publishers, Inc., London; 2004.
• [34]Andrews E, Seaman WT, Webster-Cyriaque J: Oropharyngeal carcinoma in non-smokers and non-drinkers: a role for HPV. Oral Oncol 2009, 45(6):486-491.
• [35]ZhaoD XQG, Chen XM, Fan MW: Human papillomavirus as an independent predictor in oral squamous cell cancer. Int J Oral Sci 2009, 1(3):119-25.
• [36]Hashibe M, Brennan P, Shu-chun Chuang S, Boccia S, Castellsague X, Chen C, Curado MP, Maso LD, Daudt AW, Fabianova E, Fernandez L, Wu¨nsch-Filho V, Franceschi S, Hayes RB, Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J, Eluf-eto J, Olshan AF, Purdue M, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Renato Talamini R, Wei Q, Winn DM, OxanaShangina O, Pilarska A, Zhang Z, Ferro G, Berthiller J, Boffetta P: Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009, 18(2):541-550.
• [37]Furniss CS, McClean MD, Smith JF, Bryan J, Nelson HH, Peters ES, Posner MR, Clark JR, Eisen EA, Kelsey KT: Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 2007, 120:2386-2392.
• [38]Gillison ML: Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 2007, 29:779-792.25.
• [39]IARC: IARC monographs on the evaluation of carcinogenic risks to humans, Vol85,Betel quid and areca nut chewing and some areca-nut-derived nitrosamines. IARCPress, Lyon; 2004.
• [40]Martín-Hernán F, Sánchez-Hernández JG, Cano J, Campo J, del Romero J: Oral cancer, HPV infection and evidence of sexual transmission. Med Oral Patologia Oral y CirugiaBucal 2013, 18(3):e439-e444.
• [41]Rubenstein LM, Smith EM, Pawlita P, Haugen TH, Hamšiková E, Turek LP: Human papilloma virus serologic follow-up response and relationship to survival in head and neck cancer: a case comparison study. Infect Agents Cancer 2011, 6:9. BioMed Central Full Text
• [42]Lowy DR, Munger K: Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 2010, 363:82-84.
• [43]O’Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu F-F, Chen E, Xu W: Deintensification candidate subgroups in human papillomavirus–related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013, 31:543-550.
• [44]Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM: Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001, 125:1-9.
• [45]Hudson L, Hay FC: Practical Immunology. 3rd edition. Blackwell Scientific Publications, Oxford, London, Edinburgh, Boston, Melbourne; 1989.
• [46]Christensen ND, Dillner J, Eklund C, Carter JJ, Wipf GC, Reed CA, Cladel NM, Gallowway DA: Surface Conformational and Linear Epitopes on HPV-16 and HPV-18 L1 Virus-likeParticles as Defined by Monoclonal Antibodies. Virology 1996, 223:174-184.
• [47]Karem KL, Poon AC, Bierl C, Nisenbaum R, Unger E: Optimization of a Human Papillomavirus-Specific Enzyme-Linked Immunosorbent Assay. Clin Diagn Lab Immunol 2002, 9(3):577-582.